Skip to main content
Premium Trial:

Request an Annual Quote

One New RNAi-Related Patent Application Published By US Patent Office

Premium

Title: RNAi-Based Inhibitory Oligonucleotides. Number: 20040077082. Filed: Oct. 18, 2002. Lead Inventor: Richard Koehn, Salus Therapeutics (Genta).

According to the patent application’s abstract, the invention “discloses a class of sequence-specific oligonucleotides for use in silencing genes. Specifically, the invention includes targetable oligonucleotides composed of RNA, DNA, nucleic acid analogs, or some combination … which have a configuration such that their introduction to a solution, cell, tissue, or organism containing the target gene causes silencing of the gene to which they are targeted,” the abstract adds.

“The invention also includes methods of silencing a gene by exposing a solution, cell, tissue, or organism with a compound comprising an oligonucleotide of the invention,” the abstract states. “Additionally, the invention provides recombinant vectors comprising nucleic acid molecules that code for the targeted oligonucleotides of the invention.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.